The Challenge of Acute Antibody-Mediated Rejection in Kidney Transplantation
Authors:
- Manuel PascualMPManuel Pascual
- 1 February 2016
- journal article
- editorial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (2) , 264-265
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal TransplantationTransplantation, 2016
- Eculizumab to Treat Antibody-Mediated Rejection in a 7-Year-Old Kidney Transplant RecipientPediatrics, 2015
- Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationaleTransplant International, 2012
- NK Cell Transcripts and NK Cells in Kidney Biopsies from Patients with Donor-Specific Antibodies: Evidence for NK Cell Involvement in Antibody-Mediated RejectionAmerican Journal of Transplantation, 2010
- Impact of rituximab therapy for treatment of acute humoral rejectionClinical Transplantation, 2009
- A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal TransplantationAmerican Journal of Transplantation, 2008
- Rituximab Therapy for Acute Humoral Rejection After Kidney TransplantationTransplantation, 2007
- New treatments for acute humoral rejection of kidney allograftsExpert Opinion on Investigational Drugs, 2007
- PLASMA EXCHANGE AND TACROLIMUS-MYCOPHENOLATE RESCUE FOR ACUTE HUMORAL REJECTION IN KIDNEY TRANSPLANTATION1Transplantation, 1998
- THE SIGNIFICANCE OF THE ANTI-CLASS I ANTIBODY RESPONSETransplantation, 1990